Immunotherapy for Breast Cancer — in Hyderabad

Immunotherapy for breast cancer is a treatment that helps your own immune system find and destroy cancer cells. The main type used is called a checkpoint inhibitor. Cancer cells can switch off the immune system using proteins on their surface. Checkpoint inhibitors block those off-switches, so your T-cells can see the cancer again and attack it. This is different from chemotherapy, which attacks cancer cells directly. In breast cancer, immunotherapy is almost always given together with chemotherapy — not on its own — because the two work better as a combination.

Immunotherapy is mainly used for triple-negative breast cancer (TNBC) — a subtype that does not have oestrogen, progesterone, or HER2 receptors. Because hormone therapy and HER2-targeted drugs do not work on TNBC, immunotherapy combined with chemotherapy has become an important option. It is recommended for high-risk early TNBC (before and after surgery) and for advanced or metastatic TNBC that is PD-L1 positive. For most hormone-receptor-positive or HER2-positive breast cancers, other targeted treatments are more effective and immunotherapy is not usually recommended.

PD-L1 is a protein that cancer cells and immune cells can carry. High levels of PD-L1 in the tumour mean your cancer is more likely to respond to a checkpoint inhibitor. Before recommending immunotherapy for advanced breast cancer, your oncologist will test a sample of your tumour for PD-L1 using a specific laboratory test. The result helps decide whether immunotherapy is the right choice for you, and which drug to use. For early-stage high-risk TNBC, immunotherapy may be recommended even if PD-L1 is low, because the trial evidence supports it regardless of score.

Immunotherapy can cause a group of side effects called immune-related adverse events (irAEs). These happen because the treatment switches on the immune system, which can sometimes attack healthy organs as well as cancer cells. Common ones include thyroid problems (underactive or overactive thyroid), skin rash, diarrhoea, liver inflammation, and tiredness. Most are mild and can be managed without stopping immunotherapy. Rarely, more serious reactions affecting the lungs, kidneys, or heart can occur — which is why CION tests blood and thyroid function before every cycle and gives patients a direct line to the care team if new symptoms appear between visits.

Immunotherapy is given as an intravenous infusion (a drip) in a day-care setting. You do not need to stay overnight for a routine cycle. Each infusion typically takes about 30 minutes, plus monitoring time. It is given every 3 weeks, alongside chemotherapy, on a schedule set by your tumor board. Before every cycle, you have blood tests and a doctor review to check how you are responding and whether any side effects need attention. Cashless insurance, Aarogyasri, CGHS, ECHS, and EHS are accepted at CION centres.

The indicative cost of immunotherapy for breast cancer varies depending on the drug used, the number of cycles, whether it is given before surgery, after surgery, or for advanced disease, and your insurance coverage. At CION, we provide a written cost estimate after your tumor board review — so you know exactly what to expect before you begin. CGHS, ECHS, EHS, and many corporate insurance policies cover immunotherapy. EMI options are also available. Call 1800-202-8726 or book a free consultation to get your written estimate.